Selected examples of our health economics modelling work across vaccines, rare disease, and cell therapy, anonymised at client request.
Client confidentiality: All case studies below are based on real engagements. Client names and identifying details have been anonymised at their request. The methodology, outputs, and outcomes described are accurate representations of the work delivered.
A leading European biotech required a robust, submission-ready Budget Impact Model to support the reimbursement and national immunisation programme negotiations for its tick-borne encephalitis (TBE) vaccine across multiple European markets. Existing internal models were insufficiently granular for payer scrutiny, and the timeline to submission was tight. The client needed a model that could be adapted efficiently for each target market without rebuilding from scratch.
A global pharmaceutical company developing a transformative therapy for sickle cell disease needed a rigorous Cost of Illness model to underpin its global market access strategy. Existing published literature was fragmented and inconsistent across geographies, and the client needed a robust, credible evidence base that could support payer conversations in the UK, Germany, France, and the US simultaneously, framing both the clinical and economic burden of a condition that remains significantly underserved.
A clinical-stage biotech developing a novel CAR-T cell therapy engaged Altima Partners to build its market access evidence base ahead of anticipated regulatory approval. With a first-in-class mechanism, limited long-term survival data, and a small but well-defined patient population, the modelling challenge was significant, requiring a framework that could credibly extrapolate clinical trial data, withstand HTA scrutiny, and be adapted efficiently for NICE, G-BA, and HAS submissions from a single core model.
Written from our own data and free to read. Each piece has a scrollable data story behind it, built from the same figures we use for client work.
France held the apixaban price almost still while England let it fall. Two systems, one molecule, and what the divergence cost each payer.
The same post-patent molecule priced three ways, and what each system's machinery actually rewarded.
How fast a class switches once a better molecule arrives, and what that speed does to a forecast built on the old one.
Four PBAC meetings, the evidence that changed between them, and what the sponsor conceded to get a recommendation.
Tell us about your indication, your markets, and your timeline.
We'll come back to you within one working day.